Twist Bioscience enters the week with the Street aggressively revising upward, even as a 40% one-month rally has already run well past most of those fresh targets.
The analyst angle is the defining tension right now. Barclays raised its price target to $95 from $65 on June 24 — a 46% lift in a single move — while maintaining its Overweight rating. That followed TD Cowen lifting to $89 and Canaccord Genuity initiating at Buy with a $90 target, both on June 15. Piper Sandler initiated at Overweight with an $85 target on June 11. Every recent action has been constructive; not one firm cut or downgraded. Yet with the stock closing at $85, it has already traded through several of those newly published targets, and the consensus mean sits at $74.10 — below the current price. The Street is chasing a stock that has already moved, and Barclays' $95 target is the only one that still offers meaningful upside from here.
The bull and bear cases are sharply drawn. Bulls point to Twist's silicon-based DNA synthesis platform, an underappreciated NGS segment acting as a compounding growth engine, and the prospect of margin improvement as the company moves toward profitability. The factor score on analyst recommendation divergence ranks in the 98th percentile — unusually wide disagreement on the Street about where this stock belongs. Bears focus on execution risk: the profitability narrative depends entirely on sustained gross margin improvement and cost discipline, neither of which is guaranteed. Government funding exposure adds another variable, given that any reduction in research budgets would feed directly into Twist's revenue line. The EPS surprise factor score sits at the 83rd percentile, suggesting the company has consistently beaten estimates — but EPS momentum over 30 and 90 days ranks near the bottom of the universe, a persistent drag on the scoring model.
Short interest tells a more complicated story than the bullish price action implies. Bears hold 24.1% of the free float short — a structurally high position — but that level has been coming down. Short interest fell 7% over the past week to around 14.7 million shares, after running close to 16.8 million shares in early June. The borrow market is not tight: availability has loosened sharply to 326%, well above the 52-week tightest point of 113%, meaning there is ample supply for new shorts who want to lean against the rally. Cost to borrow is a low 0.42%, down 17% on the week, reinforcing the picture of a heavily shorted but freely available name. The ORTEX short score sits at 69.9, having eased from a recent peak near 75.5 on June 15 — the direction of travel suggests short pressure is dissipating rather than building.
Options positioning has turned sharply more bullish in a matter of days. The put/call ratio has collapsed to 0.34, nearly 2.7 standard deviations below its 20-day average of 0.56 — close to its 52-week low of 0.15 and a dramatic reversal from readings above 1.0 in mid-May. That reflects heavy call-side activity relative to protective puts, consistent with momentum traders positioning for continued upside. The contrast with the still-elevated short interest is notable: options traders are leaning in, while shorts have trimmed but not exited.
Insider activity over the past 90 days runs net positive by 160,713 shares, though the picture requires some nuance. Nearly all recent individual transactions were sales: the SVP sold roughly $2.1 million worth on June 15, the CFO sold $280,000 on May 29, and the CEO sold a small tranche on June 8. These look primarily like scheduled liquidations rather than conviction-driven exits given the low trade-significance scores, but the net share figure is positive largely because of earlier acquisitions earlier in the window rather than fresh buying. Artisan Partners and ARK Investment Management each hold just over 10% of shares, giving the stock a concentrated ownership base that could amplify moves in either direction if either manager rebalances.
The next earnings event is August 3. The prior print on May 21 produced a 12.9% one-day gain and a 28.6% five-day gain — the catalyst for much of the rally now baked into the price. The print before that, on May 4, fell 6.1% the day after. With the stock up 40% in a month and analysts still revising targets higher in real time, the August report becomes the next major test of whether the NGS growth story and margin trajectory can sustain a valuation that has run well ahead of current Street consensus.
See the live data behind this article on ORTEX.
Open TWST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
